Major Depressive Disorder News and Research

RSS

Major Depressive Disorder (MDD) is a psychiatric condition characterized by depressed mood or anhedonia (significant loss of interest or pleasure). The condition affects more than 15.7 million adults and approximately 3 million adolescents (aged 13 to 17 years) in the USA each year.

New evidence questions the role of brain fog in mental health recovery

Experiences of cognitive problems such as memory loss or difficulty concentrating, known as 'brain fog', may not predict relapse in depression, according to a new study that has confounded researchers' expectations.

7 May 2026

Supportive relationships in childhood help buffer the long-term health effects of abuse

A consistent, caring adult during childhood can make a profound difference for child survivors of physical or sexual abuse.

21 Apr 2026

Researchers prove magnetic seizures are comparable to ECT in clinical response

A landmark international clinical trial led by researchers at the Centre for Addiction and Mental Health (CAMH) and University of California San Diego School of Medicine, published in The Lancet Psychiatry, has found that magnetic seizure therapy (MST) is as effective as electroconvulsive therapy (ECT)-the current gold-standard treatment for severe, treatment-resistant depression-with significantly fewer cognitive side effects. The study is the first large-scale, randomized clinical trial to directly compare MST with ECT, marking an important step toward a new treatment option for patients.

16 Apr 2026

More steps cut chronic disease risk but cannot fully undo long sitting

Research shows higher daily step counts can mitigate risks of chronic diseases linked to prolonged sitting, emphasizing the need to reduce sedentary time.

10 Apr 2026

When omega-3 may help mental health and when they may not

Investigating omega-3 fatty acids, this review highlights their impact on mental health, inflammation, and the potential for therapeutic use in disorders.

10 Apr 2026

Navigated TMS significantly boosts combat PTSD recovery rates

An advanced version of a procedure using magnetic fields to stimulate brain nerve cells in treating depression was significantly effective for 85% of active military and veterans suffering from combat post-traumatic stress disorder enrolled in a recent study, when added to psychotherapy.

7 Apr 2026

Trial tests fast-acting brain stimulation for postpartum depression treatment

The Icahn School of Medicine at Mount Sinai today announced the enrollment of its first patient in a U.S. Department of Defense-funded pivotal clinical trial to evaluate whether a fast-acting, drug-free brain stimulation therapy can safely and quickly relieve symptoms of postpartum depression.

1 Apr 2026

How could bisphenol A raise depression risk? Study identifies six key molecular targets

An integrative Translational Psychiatry study linked BPA exposure to major depressive disorder by identifying 571 shared targets and six core genes, with genetic, transcriptomic, docking, and mouse-model data supporting plausible mechanistic pathways. The strongest signals pointed to AKT1, SRC, PLCG2, and JAK3 as potential contributors, while EGFR appeared protective.

31 Mar 2026

NOX-1 identified as key molecular target to prolong ketamine's antidepressant effects

Treatment-resistant depression affects a large proportion of people with major depressive disorder, and while ketamine offers rapid relief, its antidepressant effects fade within a few weeks.

30 Mar 2026

Study maps gene activity linked to neurotransmission in living brains

Researchers have identified a distinct and reproducible gene expression program associated with neurotransmission in the living human brain, offering unprecedented insight into the molecular mechanisms that support human cognition, emotion, and behavior.

16 Mar 2026

New review calls for biologically grounded approach to psychiatric diagnosis

A comprehensive invited review published today in Brain Medicine confronts one of the most persistent paradoxes in modern medicine: psychiatry remains the only major clinical discipline that diagnoses complex illness primarily through conversation and symptom checklists, while fields such as oncology and cardiology long ago embraced laboratory markers, imaging, and molecular profiling.

10 Mar 2026

Cellular energy changes may help detect early-stage major depression

Researchers may have discovered a new way to diagnose and treat major depression at the earliest stage of the condition, giving patients the best opportunity for recovery.

10 Mar 2026

PET imaging reveals molecular mechanism behind ketamine's antidepressant effects

Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients develop treatment-resistant depression (TRD), a condition that does not respond adequately to conventional antidepressant therapies.

6 Mar 2026

Mental health struggles in first year of cancer care predict worse outcomes

This study reveals a strong association between early mental health disorders in cancer patients and increased all-cause mortality, highlighting care needs.

25 Feb 2026

Short-duration psychedelic therapy shows promise for major depression treatment

A phase IIa randomized trial found that intravenous dimethyltryptamine (DMT) with structured psychological support produced rapid reductions in depressive symptoms in adults with major depressive disorder. Improvements were statistically significant versus placebo at two weeks, with mostly mild-to-moderate adverse events and the need for larger confirmatory studies emphasized.

17 Feb 2026

Simple wrist-worn device enables early detection of depression relapse

Could a smart watch act as an early‑warning system for depression relapse? New research from McMaster University suggests that disruptions in a person's sleep and daily activity routine, as detected through a simple wrist-worn device, can signal when there is increased risk of relapsing into major depression.

11 Feb 2026

Brain connectivity fingerprints differ in major depressive disorder

Major depressive disorder (MDD) is a debilitating condition that affects more than 246 million people worldwide, yet scientists have struggled to identify consistent brain markers that could improve diagnosis and treatment.

5 Feb 2026

King’s researchers help transform UK mental health research infrastructure

King’s researchers will help transform mental health data, clinical trials and industry partnerships as part of the UK Government’s Mental Health Goals programme.

30 Jan 2026

Research reveals dual impact of brain stimulation on people with depression and anxiety

Research investigating the effects of transcranial direct current stimulation (tDCS) on individuals with depression and comorbid anxiety reveals a dual impact of this noninvasive form of brain stimulation.

29 Jan 2026

New role for GLP-1 drugs: Improving survival in people with severe psychiatric disorders

This editorial argues that GLP-1 receptor agonists could substantially improve healthspan and reduce premature mortality in people with serious mental illnesses by targeting cardiometabolic risk rather than psychiatric symptoms alone. It highlights emerging evidence, safety considerations, and equity challenges that position GLP-1 RAs as a promising public health strategy for this high-risk population.

25 Jan 2026